Association of aspartate aminotransferase with mortality in hemodialysis patients

Vanessa Ravel, Elani Streja, M. Molnár, Sepideh Rezakhani, Melissa Soohoo, Csaba P. Kovesdy, Kamyar Kalantar-Zadeh, Hamid Moradi

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

BackgroundLiver disease is a common comorbid condition in maintenance hemodialysis (MHD) patients and may be associated with poor survival. The relationship between aspartate aminotransferase (AST) and survival has not yet been addressed in these patients. We hypothesized that higher AST level is associated with higher death risk in MHD patients. MethodsA 5-year (January 2007-December 2011) cohort of 109 718 MHD patients was studied in the USA in dialysis clinics where AST was measured in at least 50% of all outpatients in the baseline calendar quarter. Survival models were adjusted for demographic variables, and available clinical and laboratory surrogates of malnutrition-inflammation complex, and cubic survival splines were plotted. ResultsA linear association existed between baseline serum AST levels and mortality. Increasing AST of >20 IU/L was incrementally and almost linearly associated with higher death risk at all levels of adjustment. In fully adjusted models, AST levels of ≥40 IU/L were associated with the highest risk of mortality (hazard ratio: 1.46, 95% CI: 1.38-1.54). Low AST levels (20 IU/L is incrementally associated with higher mortality in MHD patients whereas AST in the 15-20 IU/L range is associated with the greatest survival. These findings suggest that the assessment of liver function and improving liver disease may confer survival benefit to MHD patients.

Original languageEnglish
Pages (from-to)814-822
Number of pages9
JournalNephrology Dialysis Transplantation
Volume31
Issue number5
DOIs
Publication statusPublished - May 1 2016

Fingerprint

Aspartate Aminotransferases
Renal Dialysis
Mortality
Survival
Malnutrition
Liver Diseases
Dialysis
Outpatients
Maintenance
Demography
Inflammation
Liver
Serum

Keywords

  • all-cause mortality
  • aspartate aminotransferase
  • end-stage renal disease
  • hemodialysis
  • liver enzymes

ASJC Scopus subject areas

  • Nephrology
  • Transplantation

Cite this

Ravel, V., Streja, E., Molnár, M., Rezakhani, S., Soohoo, M., Kovesdy, C. P., ... Moradi, H. (2016). Association of aspartate aminotransferase with mortality in hemodialysis patients. Nephrology Dialysis Transplantation, 31(5), 814-822. https://doi.org/10.1093/ndt/gfv310

Association of aspartate aminotransferase with mortality in hemodialysis patients. / Ravel, Vanessa; Streja, Elani; Molnár, M.; Rezakhani, Sepideh; Soohoo, Melissa; Kovesdy, Csaba P.; Kalantar-Zadeh, Kamyar; Moradi, Hamid.

In: Nephrology Dialysis Transplantation, Vol. 31, No. 5, 01.05.2016, p. 814-822.

Research output: Contribution to journalArticle

Ravel, V, Streja, E, Molnár, M, Rezakhani, S, Soohoo, M, Kovesdy, CP, Kalantar-Zadeh, K & Moradi, H 2016, 'Association of aspartate aminotransferase with mortality in hemodialysis patients', Nephrology Dialysis Transplantation, vol. 31, no. 5, pp. 814-822. https://doi.org/10.1093/ndt/gfv310
Ravel, Vanessa ; Streja, Elani ; Molnár, M. ; Rezakhani, Sepideh ; Soohoo, Melissa ; Kovesdy, Csaba P. ; Kalantar-Zadeh, Kamyar ; Moradi, Hamid. / Association of aspartate aminotransferase with mortality in hemodialysis patients. In: Nephrology Dialysis Transplantation. 2016 ; Vol. 31, No. 5. pp. 814-822.
@article{ce649ca590334926b613e4b6b5b6144c,
title = "Association of aspartate aminotransferase with mortality in hemodialysis patients",
abstract = "BackgroundLiver disease is a common comorbid condition in maintenance hemodialysis (MHD) patients and may be associated with poor survival. The relationship between aspartate aminotransferase (AST) and survival has not yet been addressed in these patients. We hypothesized that higher AST level is associated with higher death risk in MHD patients. MethodsA 5-year (January 2007-December 2011) cohort of 109 718 MHD patients was studied in the USA in dialysis clinics where AST was measured in at least 50{\%} of all outpatients in the baseline calendar quarter. Survival models were adjusted for demographic variables, and available clinical and laboratory surrogates of malnutrition-inflammation complex, and cubic survival splines were plotted. ResultsA linear association existed between baseline serum AST levels and mortality. Increasing AST of >20 IU/L was incrementally and almost linearly associated with higher death risk at all levels of adjustment. In fully adjusted models, AST levels of ≥40 IU/L were associated with the highest risk of mortality (hazard ratio: 1.46, 95{\%} CI: 1.38-1.54). Low AST levels (20 IU/L is incrementally associated with higher mortality in MHD patients whereas AST in the 15-20 IU/L range is associated with the greatest survival. These findings suggest that the assessment of liver function and improving liver disease may confer survival benefit to MHD patients.",
keywords = "all-cause mortality, aspartate aminotransferase, end-stage renal disease, hemodialysis, liver enzymes",
author = "Vanessa Ravel and Elani Streja and M. Moln{\'a}r and Sepideh Rezakhani and Melissa Soohoo and Kovesdy, {Csaba P.} and Kamyar Kalantar-Zadeh and Hamid Moradi",
year = "2016",
month = "5",
day = "1",
doi = "10.1093/ndt/gfv310",
language = "English",
volume = "31",
pages = "814--822",
journal = "Nephrology Dialysis Transplantation",
issn = "0931-0509",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Association of aspartate aminotransferase with mortality in hemodialysis patients

AU - Ravel, Vanessa

AU - Streja, Elani

AU - Molnár, M.

AU - Rezakhani, Sepideh

AU - Soohoo, Melissa

AU - Kovesdy, Csaba P.

AU - Kalantar-Zadeh, Kamyar

AU - Moradi, Hamid

PY - 2016/5/1

Y1 - 2016/5/1

N2 - BackgroundLiver disease is a common comorbid condition in maintenance hemodialysis (MHD) patients and may be associated with poor survival. The relationship between aspartate aminotransferase (AST) and survival has not yet been addressed in these patients. We hypothesized that higher AST level is associated with higher death risk in MHD patients. MethodsA 5-year (January 2007-December 2011) cohort of 109 718 MHD patients was studied in the USA in dialysis clinics where AST was measured in at least 50% of all outpatients in the baseline calendar quarter. Survival models were adjusted for demographic variables, and available clinical and laboratory surrogates of malnutrition-inflammation complex, and cubic survival splines were plotted. ResultsA linear association existed between baseline serum AST levels and mortality. Increasing AST of >20 IU/L was incrementally and almost linearly associated with higher death risk at all levels of adjustment. In fully adjusted models, AST levels of ≥40 IU/L were associated with the highest risk of mortality (hazard ratio: 1.46, 95% CI: 1.38-1.54). Low AST levels (20 IU/L is incrementally associated with higher mortality in MHD patients whereas AST in the 15-20 IU/L range is associated with the greatest survival. These findings suggest that the assessment of liver function and improving liver disease may confer survival benefit to MHD patients.

AB - BackgroundLiver disease is a common comorbid condition in maintenance hemodialysis (MHD) patients and may be associated with poor survival. The relationship between aspartate aminotransferase (AST) and survival has not yet been addressed in these patients. We hypothesized that higher AST level is associated with higher death risk in MHD patients. MethodsA 5-year (January 2007-December 2011) cohort of 109 718 MHD patients was studied in the USA in dialysis clinics where AST was measured in at least 50% of all outpatients in the baseline calendar quarter. Survival models were adjusted for demographic variables, and available clinical and laboratory surrogates of malnutrition-inflammation complex, and cubic survival splines were plotted. ResultsA linear association existed between baseline serum AST levels and mortality. Increasing AST of >20 IU/L was incrementally and almost linearly associated with higher death risk at all levels of adjustment. In fully adjusted models, AST levels of ≥40 IU/L were associated with the highest risk of mortality (hazard ratio: 1.46, 95% CI: 1.38-1.54). Low AST levels (20 IU/L is incrementally associated with higher mortality in MHD patients whereas AST in the 15-20 IU/L range is associated with the greatest survival. These findings suggest that the assessment of liver function and improving liver disease may confer survival benefit to MHD patients.

KW - all-cause mortality

KW - aspartate aminotransferase

KW - end-stage renal disease

KW - hemodialysis

KW - liver enzymes

UR - http://www.scopus.com/inward/record.url?scp=84965167738&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84965167738&partnerID=8YFLogxK

U2 - 10.1093/ndt/gfv310

DO - 10.1093/ndt/gfv310

M3 - Article

C2 - 26333544

AN - SCOPUS:84965167738

VL - 31

SP - 814

EP - 822

JO - Nephrology Dialysis Transplantation

JF - Nephrology Dialysis Transplantation

SN - 0931-0509

IS - 5

ER -